pralnacasan has been researched along with troglitazone in 2 studies
| Studies (pralnacasan) | Trials (pralnacasan) | Recent Studies (post-2010) (pralnacasan) | Studies (troglitazone) | Trials (troglitazone) | Recent Studies (post-2010) (troglitazone) |
|---|---|---|---|---|---|
| 19 | 0 | 7 | 1,857 | 146 | 287 |
| Protein | Taxonomy | pralnacasan (IC50) | troglitazone (IC50) |
|---|---|---|---|
| Bile salt export pump | Rattus norvegicus (Norway rat) | 3.9 | |
| Bile salt export pump | Homo sapiens (human) | 5.05 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.97 | |
| Adenosine receptor A3 | Homo sapiens (human) | 5.208 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 5.208 | |
| Thromboxane-A synthase | Homo sapiens (human) | 2.966 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 2.07 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 1.238 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 1.03 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.312 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 5.208 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 1.285 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 1.285 | |
| Indoleamine 2,3-dioxygenase 2 | Mus musculus (house mouse) | 4.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for pralnacasan and troglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for pralnacasan and troglitazone
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |